	US 12,029,759 B2
	Compositions and methods for treating neurological disorders
Benjamin M. Segal, Ann Arbor, MI (US); Andrew Sas, Ann Arbor, MI (US); and Kevin Carbajal, Ann Arbor, MI (US)
Assigned to The Regents of the University of Michigan, Ann Arbor, MI (US)
Appl. No. 16/965,816
Filed by THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
PCT Filed Jan. 31, 2019, PCT No. PCT/US2019/016027 § 371(c)(1), (2) Date Jul. 29, 2020, PCT Pub. No. WO2019/152636, PCT Pub. Date Aug. 8, 2019.
Claims priority of provisional application 62/624,444, filed on Jan. 31, 2018.
Prior Publication US 2021/0113611 A1, Apr. 22, 2021
Int. Cl. A61K 35/15 (2015.01); C12N 5/0787 (2010.01)

CPC A61K 35/15 (2013.01) [C12N 5/0642 (2013.01); C12N 2500/34 (2013.01); C12N 2501/105 (2013.01); C12N 2501/13 (2013.01); C12N 2501/15 (2013.01)]

13 Claims

1. A method of treating or preventing a neurological disorder, comprising: administering a plurality of Ly6G^lowCD14⁺ neutrophils or a secreted product thereof to a subject diagnosed with or at risk of a neurological disorder under conditions such that said neurological disorder is treated or prevented, wherein the secreted product is conditioned media harvested from cultures of said neutrophils.